BRKR
Bruker Corporation
BRKR lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
BRKR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Weak |
BRKR's cash flow is currently healthy, and its revenue is stable, but its profitability and balance sheet are under pressure.
BRKR PE Valuation
BRKR has no meaningful PE right now: it lost money over the past year.
BRKR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect BRKR's earnings to grow and its profitability to improve, with its revenue holding steady.
BRKR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.34 | — |
| Q3 2026 | -$1.10 | -$0.94 |
| Q2 2026 | -$0.70 | -235% |
| Q1 2026 | -$0.24 | -146% |
| Q4 2025 | -$0.15 | -120% |
| Q3 2022 | $1.82 | +3.4% |
| Q2 2022 | $1.80 | +17% |
| Q1 2022 | $1.85 | +40% |
| Q4 2021 | $1.81 | +77% |
BRKR lost $1.10 per share over the past year, and its loss has widened in each of the last three quarters.
BRKR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $874M | +1.6% |
| Q2 2026 | $838.5M | +5.2% |
| Q1 2026 | $823.4M | +2.7% |
| Q4 2025 | $977.2M | -0.2% |
| Q3 2025 | $860.5M | -0.5% |
| Q2 2025 | $797.4M | -0.4% |
| Q1 2025 | $801.4M | +11% |
| Q4 2024 | $979.6M | +15% |
BRKR's revenue grew through 2024 and has held roughly level since: $874M last quarter, up 1.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | -4.4 points |
| Q2 2026 | -7.8% | -9.3 points |
| Q1 2026 | 1.2% | -2.7 points |
| Q4 2025 | 7.8% | +0.4 points |
| Q3 2025 | -6% | -14 points |
| Q2 2025 | 1.5% | -4.5 points |
| Q1 2025 | 4% | -5 points |
| Q4 2024 | 7.4% | -4.7 points |
BRKR's operating margin was −10% last quarter, down 4.4 points from the same quarter a year ago, near the bottom of its range since 2019.
BRKR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $96.7M | +$150.8M |
| Q2 2026 | -$106.2M | +$42.6M |
| Q1 2026 | $47M | +21% |
| Q4 2025 | $207.2M | +35% |
| Q3 2025 | -$54.1M | -1033% |
| Q2 2025 | -$148.8M | -$125.3M |
| Q1 2025 | $39M | +9650% |
| Q4 2024 | $153.3M | -12% |
BRKR's free cash flow has turned positive again: $245M over the past year, against −$11M the year before.
BRKR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.0x | High |
| Q2 2026 | 8.2x | High |
| Q1 2026 | 5.6x | High |
| Q4 2025 | 5.4x | High |
| Q3 2025 | 6.2x | High |
| Q2 2025 | 5.9x | High |
| Q1 2025 | 4.6x | High |
| Q4 2024 | 4.4x | High |
BRKR's net debt is about 10 years of its operating earnings (EBITDA), up from 6.2 years a year ago.
BRKR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.3 | Neutral |
| Stochastic | 52.9 | Neutral |
BRKR's weekly RSI is 55 (neutral) and its Stochastic is 53 (neutral).
BRKR PE vs Healthcare Sector
| Metric | BRKR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BRKR has no meaningful PE right now: it lost money over the past year.
BRKR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.7 | 1.1% above |
| 20 week MA | $59.1 | 2.1% above |
| 50 week MA | $50.4 | 20% above |
| 100 week MA | $46.4 | 30% above |
| 200 week MA | $58.3 | 3.6% above |
BRKR has climbed back above all five of its weekly moving averages, and it's now 3.6% above its 200-week average.
BRKR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.0 | $54.3 | +6.6% |
| 2021 | $54.3 | $80.3 | +48% |
| 2022 | $80.3 | $66.5 | -17% |
| 2023 | $66.5 | $73.5 | +10% |
| 2024 | $73.5 | $58.4 | -21% |
| 2025 | $58.4 | $48.0 | -18% |
| 2026 YTD | $48.0 | $60.3 | +26% |
BRKR has finished lower in three of the last six years. It's up 26% so far in 2026.